Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
31.3M
-
Shares change
-
+31.3M
-
Total reported value, excl. options
-
$1.3B
-
Value change
-
+$1.3B
-
Number of buys
-
70
-
Price
-
$41.67
Significant Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q1 2021
70 filings reported holding CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2021.
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.3M shares
of 59M outstanding shares and own 53.13% of the company stock.
Largest 10 shareholders include MPM Oncology Impact Management LP (7.91M shares), Foresite Capital Management V, LLC (2.73M shares), CHI Advisors LLC (2.2M shares), BAUPOST GROUP LLC/MA (1.84M shares), FMR LLC (1.22M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.21M shares), VR Adviser, LLC (1.18M shares), VANGUARD GROUP INC (1.15M shares), ORBIMED ADVISORS LLC (1.15M shares), and Rock Springs Capital Management LP (1.08M shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.